Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth
出版年份 2017 全文链接
标题
Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth
作者
关键词
-
出版物
LEUKEMIA
Volume 31, Issue 12, Pages 2686-2694
出版商
Springer Nature
发表日期
2017-05-22
DOI
10.1038/leu.2017.152
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts
- (2017) Sang Wan Kim et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
- (2016) J. Delgado-Calle et al. CANCER RESEARCH
- Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin
- (2016) Amy Y Sato et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor
- (2016) Jesus Delgado-Calle et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease
- (2016) Homare Eda et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Osteocytic signalling pathways as therapeutic targets for bone fragility
- (2016) Lilian I. Plotkin et al. Nature Reviews Endocrinology
- Pathogenesis beyond the cancer clone(s) in multiple myeloma
- (2015) G. Bianchi et al. BLOOD
- The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors
- (2015) Denise Toscani et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone
- (2015) Xiaolin Tu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody
- (2014) Xiaodong Li et al. ENDOCRINOLOGY
- Treatment of multiple myeloma bone disease: experimental and clinical data
- (2014) Yvonne Mary Papamerkouriou et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density
- (2014) Michael R. McClung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of bone disease in multiple myeloma
- (2014) Evangelos Terpos et al. Expert Review of Hematology
- Role of osteocytes in multiple myeloma bone disease
- (2014) Jesus Delgado-Calle et al. Current Opinion in Supportive and Palliative Care
- Osteocyte-Driven Bone Remodeling
- (2013) Teresita Bellido CALCIFIED TISSUE INTERNATIONAL
- The Osteocyte: An Endocrine Cell … and More
- (2013) Sarah L. Dallas et al. ENDOCRINE REVIEWS
- Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study
- (2013) Desmond Padhi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- WNT signaling in bone homeostasis and disease: from human mutations to treatments
- (2013) Roland Baron et al. NATURE MEDICINE
- Bone effects of cancer therapies
- (2013) Rebecca Silbermann et al. Current Opinion in Supportive and Palliative Care
- Multiple myeloma
- (2013) Shahrooz Eshaghian et al. Current Opinion in Supportive and Palliative Care
- Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
- (2012) Hua Zhu Ke et al. ENDOCRINE REVIEWS
- Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
- (2012) David W Dempster et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation
- (2012) N Giuliani et al. LEUKEMIA
- Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease
- (2011) S. D'Souza et al. BLOOD
- Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats
- (2011) Xiaodong Li et al. ENDOCRINOLOGY
- Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy
- (2011) Evangelos Terpos et al. INTERNATIONAL JOURNAL OF CANCER
- Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by -Catenin
- (2011) W. Wei et al. MOLECULAR AND CELLULAR BIOLOGY
- Glucocorticoid-Induced Bone Disease
- (2011) Robert S. Weinstein NEW ENGLAND JOURNAL OF MEDICINE
- Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
- (2011) Asiri R. Wijenayaka et al. PLoS One
- Targeting the bone microenvironment in multiple myeloma
- (2010) G. David Roodman JOURNAL OF BONE AND MINERAL METABOLISM
- Osteoblastogenesis and tumor growth in myeloma
- (2010) Shmuel Yaccoby LEUKEMIA & LYMPHOMA
- Bortezomib induces osteoblast differentiation via Wnt-independent activation of -catenin/TCF signaling
- (2009) Y.-W. Qiang et al. BLOOD
- Wnt signaling control of bone cell apoptosis
- (2008) Peter V N Bodine CELL RESEARCH
- Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength
- (2008) Xiaodong Li et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
- (2008) Deborah J Heath et al. JOURNAL OF BONE AND MINERAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started